PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

Heart Failure Clinical Trial

Official title:

Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00682565
• Other study ID #: CY 1221
• Status: Completed
• Phase: Phase 2
• Start date: April 2008
• Est. completion date: March 2009

Study information

• Verified date: February 2010
• Source: Cytokinetics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigates whether symptom-limited exercise capacity in ischemic cardiomyopathy patients with angina is deleteriously affected by treatment with CK-1827452.

Description:

The primary objective of this study is to assess the effect of intravenous (i.v.) CK-1827452 on symptom-limited exercise tolerance in patients with ischemic cardiomyopathy and angina. The secondary objectives are to assess the tolerability of CK-1827452 administered three times daily (tid) to steady state in an immediate-release (IR), blend-in-capsule oral formulation to outpatients with ischemic cardiomyopathy and angina and to assess CK-1827452 plasma concentrations at trough and 1 hour after dosing with CK-1827452 administered tid to steady state in an IR, blend-in-capsule oral formulation to outpatients with ischemic cardiomyopathy and angina.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 94
• Est. completion date: March 2009
• Est. primary completion date: November 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient has signed an Informed Consent Form/Patient Information Sheet for this study approved by the governing Institutional Review Board (IRB) or Independent Ethics Committee (IEC).

2. The patient is at least 18 years old.

3. The patient has ischemic heart disease documented by any one or more of the following:

• A history of myocardial infarction documented by elevated CPK-MB, troponin I or T, or the presence of electrocardiographic Q waves consistent with myocardial infarction.

• Coronary angiography demonstrating at least 1 major epicardial coronary artery (i.e., left main, left anterior descending, left circumflex, or right coronary artery) with a stenosis of at least 60% diameter or greater but excluding stenosis of the left main coronary artery unless revascularized by coronary artery bypass grafting.

4. The patient has a history of = 1 episode of exercise induced angina within 2 months prior to the initial screening visit.

5. The patient has been taking a beta blocker and an ACE inhibitor (and/or an ARB) for at least 4 weeks. If prescribed, diuretics must have been administered for at least 4 weeks prior to the initial screening visit.

6. The patient is NYHA Class II-III at the time of enrollment and has been so for = 3 months prior to the initial screening visit.

7. The patient has a history of a left ventricular ejection fraction (LVEF) = 35%.

8. The patient has a history of EITHER a left ventricular end-diastolic diameter = 55 mm, OR a left ventricular end-diastolic diameter index = 32 mm/m2.

9. The patient can be expected to complete at least 4 minutes of a Modified Naughton ETT (see Appendix B).

10. For female patients only: The patient is post-menopausal (= 1 year) or sterilized, or if she is of childbearing potential, she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant during the course of the study, and she is using contraceptive drugs or devices.

Exclusion Criteria:

1. The patient has acute myocarditis; clinically significant restrictive, constrictive, or hypertrophic obstructive cardiomyopathy; or clinically significant congenital heart disease.

2. The patient has a SBP > 160 mmHg, documented on at least 3 separate occasions, at least 10 minutes apart.

3. The patient has a DBP > 90 mmHg, documented on at least 3 separate occasions, at least 10 minutes apart.

4. The patient has levels of troponin I or T, or CPK-MB > the upper limit of normal at any time from 6 weeks prior to the Initial Screening Visit (Visit 1) and up to randomization.

5. The patient has severe aortic or mitral stenosis.

6. The patient has had an acute coronary syndrome, transient ischemic attack, or revascularization procedure within 6 weeks of the Initial Screening Visit (Visit 1).

7. The patient has significant co-morbid conditions (i.e., lung disease, arthritis, peripheral vascular disease) that may limit his or her treadmill exercise capacity.

8. The patient has renal impairment defined by a calculated creatinine clearance < 30 cc/min or a need for renal replacement therapy.

9. The patient has known hepatic impairment defined by a total bilirubin > 3 mg/dL, or an ALT or AST > 2 times the upper limit of normal.

10. The patient has received an investigational drug or device within 30 days or 5 half-lives, whichever is greater, of randomization.

11. The patient weighs > 120 kg.

12. The patient has a body temperature > 38 ° C, confirmed by at least 2 successive measurements, at least 10 minutes apart.

13. The patient has any laboratory abnormality which, in the opinion of the investigator, should preclude his or her participation in the study.

14. The patient has had any prior treatment with CK-1827452.

Related Conditions & MeSH terms

• Angina Pectoris
• Cardiomyopathies
• Coronary Artery Disease
• Heart Failure
• Ischemia
• Myocardial Ischemia

Intervention

Drug:
• CK-1827452 24mg and 6 mg iv infusion
I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
• CK-1827452 12.5mg capsule
12.5mg oral immediate release capsule
• CK-1827452 48 mg and 11 mg iv infusion
I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
• CK-1827452 25mg capsule
25mg oral immediate release capsule
• Placebo iv infusion
Matching placebo iv infusion
• Placebo capsule
Matching placebo oral immediate release capsule

Locations

Country	Name	City	State
Georgia	Cardio-Reanimation Centre	Tbilisi
Georgia	Cardiology Clinic	Tbilisi
Georgia	Diagnostic Services Clinic	Tbilisi
Georgia	Multiprofile Clinical Hospital of Tbilisi #2	Tbilisi
Georgia	National Center of Therapy	Tbilisi
Georgia	Tbilisi State Medical University Clinic #1	Tbilisi
Russian Federation	Altay Territory Cardiology Dispensary	Barnaul
Russian Federation	City Hospital #1	Barnaul
Russian Federation	City Clinical Hospital #59	Moscow
Russian Federation	City Clinical Hospital #64	Moscow
Russian Federation	Moscow Municipal Clinical Hospital #4	Moscow
Russian Federation	Federal Center of Heart, Blood and Endocrinology n.a. Almazov	St. Petersburg
Russian Federation	Research Centre for Cardiology n.a. Almazov under Roszdrav	St. Petersburg
Russian Federation	Volgograd Regional Cardiology Center	Volgograd

Sponsors (1)

Lead Sponsor	Collaborator
Cytokinetics

Countries where clinical trial is conducted

Georgia,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)	The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.	1 day
Secondary	Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B	The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.	1 day
Secondary	Increase in Exercise Duration During ETT-3 vs. ETT-B		1 day
Secondary	Participants Stopping ETT-3 for Angina at Any Stage	This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B.; Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina.	1 day
Secondary	Participants With 1 mm ST Segment Depression During ETT-3	ST Segment Depression measured by Electrocardiography while performing ETT-3.	1 day